CLINICAL & PIPELINE·Drug Approval
Kenvue Brands Secures Latest FDA Labeling Approval for ZYRTEC (Cetirizine Hydrochloride) NDA021621
Kenvue Brands has received FDA approval for a significant labeling supplement (submission 18) for its ZYRTEC (Cetirizine Hydrochloride) NDA021621 on March 24, 2026. This regulatory update is crucial for maintaining compliance and market positioning of a key over-the-counter antihistamine, impacting procurement and regulatory strategies for global chemical and life sciences stakeholders.
90-Day Activity